Public Meeting: Optimizing FDA’s Use of and Processes for Advisory Committees (Afternoon Portion)
Рет қаралды 2,451
Күн бұрынThe purpose of the Jun 13, 2024 listening session was to provide an open and transparent platform to solicit feedback on the FDA’s use of and processes for its advisory committee system. To facilitate input, the FDA developed a series of topics covering the types of information that the agency was interested in obtaining:
• Topic 1: Composition of Advisory Committees
• Topic 2: Service on an Advisory Committee as a Special Government Employee (SGE)
• Topic 3: Public Perception and Understanding of Advisory Committees
Related Resources:
• Federal Register Notice for the Public Meeting - www.federalreg...
• FDA to Hold Listening Session as Part of Broader Work to Optimize Use of, and Processes for, Advisory Committees - www.fda.gov/ne...
U.S. Food and Drug Administration
Рет қаралды 1,8 М.
The Current Status of Oral Phenylephrine as a Nasal Decongestant with Dr. Theresa Michele and Dr....
U.S. Food and Drug Administration
Рет қаралды 1,9 М.
U.S. Food and Drug Administration
Рет қаралды 2,1 М.
FDA D.I.S.C.O. Burst Edition: FDA approval of Retevmo (selpercatinib) for advanced or metastatic ...
U.S. Food and Drug Administration
Рет қаралды 1,7 М.
FDA D.I.S.C.O. Burst Edition: FDA approval of Ojemda (tovorafenib) for relapsed or refractory ped...
U.S. Food and Drug Administration
Рет қаралды 4,4 М.
U.S. Food and Drug Administration
Рет қаралды 63
U.S. Food and Drug Administration
Рет қаралды 75
U.S. Food and Drug Administration
Рет қаралды 151